Efficacy of Sambucol in the Treatment of Influenza

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by Hadassah Medical Organization.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Razei Bar industries Ltd.
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00375115
First received: September 10, 2006
Last updated: November 5, 2007
Last verified: October 2007

September 10, 2006
November 5, 2007
September 2006
Not Provided
The length of time to resolution of influenza illness
Same as current
Complete list of historical versions of study NCT00375115 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Efficacy of Sambucol in the Treatment of Influenza
Efficacy of Sambucol on the Length of Time to Resolution of Influenza Illness

The trial will examine the efficacy of sambucol in the treatment of influenza. The primary efficacy endpoint will be the length of time to resolution of influenza illness.The double blind trial will be conducted at the Personnel Clinic, and at the Clinical virology Unit, Hadassah University Hospital, and will include 100 patients with laboratory-confirmed influenza infection, 50 in the sambucol and 50 in the placebo study arm.

The trial will be conducted at the Personnel Clinic, and at the Clinical virology Unit, Hadassah University Hospital.

Candidates for participation in the trial :

Patients who will present at the clinic with influenza-like symptoms; men and women ages 20 yrs- 65 yrs who will sign written informed consent

Excluded from the trial will be:

  • Pregnant women or women who cannot exclude pregnancy.
  • Patients with diabetes.
  • Immune-suppressed patients, including patients taking immunosuppressive drugs.
  • Patients with renal failure.
  • Patients who received the recent influenza vaccine.

The study participants will receive treatment (either Sambucol or placebo) for five days. The follow-up period will be 10 days. All patients initially included in the trial will be followed for 10 days.

Inclusion criteria:

  • Fever ≥ 380C.
  • The presence of at least one of the following respiratory symptoms: cough, sore throat, nasal congestion/ runny nose.
  • The presence of at least one of the following systemic symptoms: headache, fatigue, myalgia, chills/sweats, malaise.

Study Patients A total of 100 patients with laboratory-confirmed influenza infection will be included in the study (50 in each study arm).

This calculation is based on the expected percentage of recovery within 3 days from initial treatment (allowing that 80% of patients given the active component will show improvement as opposed to 50% of placebo patients).

Assuming that 50% of the patients presenting with influenza-like illness will have a laboratory-confirmed influenza infection, a total number of 200 patients is expected.

The primary efficacy endpoint will be the length of time to resolution of influenza illness (defined as the period from start of study drug to the relief of symptoms).

Study design:

  1. Patients presenting at the clinic with the above indicated inclusion criteria will be referred by the clinic nurse to a physician to establish the diagnosis
  2. The temperature, the presence and severity of influenza symptoms including cough, nasal obstruction, sore throat, fatigue, headache, myalgia will be recorded on a four-point scale (0-absent, 1-mild, 2-moderate, 3-severe). Patients will also record their ability to do their normal activities, overall health status, and sleep quality on a ten-point scale (0-unable or worst, to 10-fully able, best)
  3. For influenza detection, nose and throat swabs will be collected at baseline.
  4. Patients will be randomly assigned to receive either Sambucol or placebo (15 cc 4 times daily for 5 days).
  5. Patients will be instructed that relief medications (Acamol /Optalgin) will be taken only as required, and that their use should be recorded.
  6. The follow-up will include all the parameters (see "2") recorded daily at days 1-5, at day 7, and at day 10.
  7. Compliance with the study drug will be recorded.
  8. In case the patient's condition deteriorates, the patient will be examined at the clinic to rule out the presence of complications (such as pneumonia, sinusitis, or bronchitis).
  9. Statistical analysis will include the duration and severity of the symptoms as well as the use of relief medications.

Laboratory diagnosis of influenza infection:

Combined nose and throat specimens will be tested for the presence of influenza virus at the Clinical Virology Unit by real-time PCR, following viral RNA extraction, using the TaqMan ABI 7900 instrument. Primers and fluorescent probes specific for influenza A and B viruses will be employed in a multiplex reaction.

Specimens found positive for influenza by real-time PCR will be further subjected to influenza culture on MDCK cells.

The recovered influenza viruses will be subtyped by hemagglutination inhibition, using specific antisera obtained from the WHO, or by multiplex reverse transcription (RT)- PCR reaction, using specific primers for influenza B as well as for the different influenza A H and N.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Influenza
Drug: Sambucol
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
100
September 2009
Not Provided

Inclusion Criteria:

  • Fever ≥ 380C.
  • The presence of at least one of the following respiratory symptoms: cough, sore throat, nasal congestion/ runny nose.
  • The presence of at least one of the following systemic symptoms: headache, fatigue, myalgia, chills/sweats, malaise.

Exclusion Criteria:

  • Pregnant women or women who cannot exclude pregnancy.

    • Patients with diabetes.
    • Immune-suppressed patients, including patients taking immunosuppressive drugs.
    • Patients with renal failure.
    • Patients who received the recent influenza vaccine.
Female
20 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00375115
360HMO-CTIL
Not Provided
Not Provided
Hadassah Medical Organization
Razei Bar industries Ltd.
Principal Investigator: Dana G Wolf, MD Hadassah Medical Organization
Hadassah Medical Organization
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP